HOOKIPA Reports the First Patient Dosing in P-Ib Study of HB-500 to Treat HIV
Shots:
- HOOKIPA has dosed the first patient with HB-500 under the P-Ib study for which it received a non-dilutive milestone payment of $5M as per an agreement with Gilead. HOOKIPA will conclude the P-I study with Gilead carrying out further development
- The P-Ib study aims to determine the safety, tolerability, reactogenicity & immunogenicity of repeated HB-500 doses among HIV patients on suppressive antiretroviral treatment, with recruitment underway
- HB-500 consists of two genetically engineered replicating vectors from the Pichinde virus & lymphocytic choriomeningitis virus to transfer HIV antigens from highly conserved regions of HIV-1 clade B proteins
Ref: HOOKIPA | Image: HOOKIPA
Related News:- The US FDA Approves the Label Update of Gilead’s Biktarvy for Pregnant Adults with HIV
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
